2017 Fiscal Year Final Research Report
The effect of factor Xa inhibitor on human platelets
| Project/Area Number |
16K20001
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Keywords | ビタミンK非依存性抗凝固薬（NOACs） / 活性型血液凝固第X因子（FXa）阻害薬 |
|---|
| Outline of Final Research Achievements |
Selective inhibitors of factor Xa (FXa) are widely recognized as useful therapeutic tools for stroke prevention in non-valvular atrial fibrillation or venous thrombosis. However, little is known whether FXa inhibitors directly affect the function of human platelets. In the present study, we investigated the direct effect of FXa inhibitor on the collagen-induced human platelet activation.
Rivaroxaban as well as edoxaban significantly reduced the collagen-induced phosphorylation of both HSP27 and p44/p42 MAP kinase without affecting the platelet aggregation. In patients administrated with rivaroxaban, the collagen-induced levels of phosphorylated HSP27 were markedly diminished after 2 days of administration. These results strongly suggest that FXa inhibitor reduces the collagen-stimulated release of phosphorylated HSP27 from human platelets due to the inhibition of HSP27 phosphorylation via p44/p42 MAP kinase.
|
| Free Research Field |
脳神経外科
|
